'Well-Established' Eye Health Company Bausch + Lomb Gets Outperform Rating From This Analyst

  • RBC Capital markets initiated coverage on Bausch + Lomb Corp BLCO with an Outperform rating and a $22 price target. 
  • The analysts see B+L as a diversified ophthalmology company with strong brand equity, reaping the rewards of over $2 billion of investment since 2018 through several new product launches and expected margin improvement. 
  • The company is a well-established eye health company operating in the $50 billion vision care, surgical, and pharmaceutical markets.
  • RBC notes that some gaps in its product suite should be resolved over ~24 months, permitting B+L to better leverage its high brand equity and achieve or may exceed its targeted 4-5% revenue growth over time.
  • "We recognize the shares may be volatile in the near-term based on the outcome of the BHC Xifaxan patent trial (decision likely by mid-August), which will potentially influence the timing/decision regarding the expected 80% BLCO distribution by Bausch Health Companies Inc BHC." RBC writes.
  • Price Action: BLCO shares are down 3.79% at $15.48 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: NewsHealth CareInitiationAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!